Evolocumab doesn't affect cognition when added to statins

Evolocumab doesn't affect cognition when added to statins

(HealthDay)—There is no significant difference in cognitive function for patients treated with evolocumab or placebo added to statin therapy, according to a study published in the Aug. 17 issue of the New England Journal of Medicine.

Robert P. Giugliano, M.D., from Brigham and Women's Hospital in Boston, and colleagues prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated battery in a subgroup of patients from a randomized placebo-controlled trial of evolocumab added to statin therapy. Cognitive function assessments were conducted at baseline, week 24, yearly, and at the end of the trial.

The researchers found that the mean change from baseline over time in the raw score for the spatial working memory strategy index of executive function was −0.21 ± 2.62 and −0.29 ± 2.81 in the evolocumab and placebo groups, respectively (P < 0.001 for noninferiority; P = 0.85 for superiority), among 1,204 patients followed for a median of 19 months. No significant between-group differences were seen in the secondary end points of working memory, episodic memory, or psychomotor speed. No associations were seen between levels and cognitive changes in an exploratory analysis.

"In a randomized trial involving patients who received either evolocumab or placebo in addition to , no significant between-group difference in cognitive function was observed over a median of 19 months," the authors write.

The study was funded by Amgen, the manufacturer of evolocumab.

Explore further

PCSK9 inhibitor evolocumab not associated with decline in memory or cognitive function

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: New England Journal of Medicine

Copyright © 2017 HealthDay. All rights reserved.

Citation: Evolocumab doesn't affect cognition when added to statins (2017, August 17) retrieved 29 January 2020 from https://medicalxpress.com/news/2017-08-evolocumab-doesnt-affect-cognition-added.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments